Lv21
118 积分 2025-10-08 加入
Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
1分钟前
求助中
Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors
6分钟前
已完结
Predicting steroid treatment benefit in IgA nephropathy: are we ready for precision care?
11分钟前
求助中
Sibeprenlimab: First Approval
37分钟前
已完结
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study
29天前
已完结
Iptacopan in IgA Nephropathy — Final 24-Month Data
29天前
已完结
Targeting the Pathogenesis of IgA Nephropathy — A New Treatment Approach?
1个月前
已完结
The expanding role of complement inhibitors in the treatment of IgA nephropathy
1个月前
已完结
Ravulizumab in IgA Nephropathy
1个月前
已关闭
Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?
1个月前
已完结
皖公网安备34019202002308
